Novo Nordisk has seen strong demand for its semaglutide ... in June, announced its plan to invest $4.1 billion to build a facility in Clayton, North Carolina, to produce treatments for people ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

It's in Novo Nordisk's best interest to produce more winning ... which acts as a drug delivery system, with the plan being for ambient cellular machinery within the patient's body to handle ...

Senators grilled the top executive of Novo Nordisk over why the Danish company ... by the vast majority of private health insurance plans, as well as Medicare and Medicaid, the government health ...

Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Novo Nordisk (NVO) CEO Lars Jørgensen told lawmakers Tuesday he was willing to sit down with pharmacy benefit managers (PBMs) to discuss a lower price for Wegovy and Ozempic, the company's ...

It comes after North Carolina cut the weight-loss drugs from its state health plan. Senators on the U.S. Senate Health, Education, Labor and Pensions Committee questioned Novo Nordisk CEO Lars ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk Chief Executive Lars Jorgensen defended his company's U.S. pricing for the blockbuster drugs Ozempic and Wegovy despite pressure from senators to make the drugs cheaper. The CEO on ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a ...